Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Expanded_access × revumenib × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Interventional 5 Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1 Leukemia 1

Interventions

nilotinib 4 dabrafenib 4 Nivolumab 4 Afatinib 4 trametinib 3 midostaurin 3 elotuzumab 3 3-Iodobenzylguanidine 3 venetoclax 2 tucatinib 2 tempol 2 talimogene laherparepvec 2 ruxolitinib 2 regorafenib 2 pomalidomide 2 olaparib 2 niraparib 2 lenvatinib 2 ibrutinib 2 gilteritinib 2 ceritinib 2 brexucabtagene autoleucel 2 balstilimab 2 axicabtagene ciloleucel 2 avapritinib 2 atezolizumab 2 abemaciclib 2 Trastuzumab 2 Suspensions 2 Sunitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available

Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡